Recalls in the food and beverage industry due to contamination incidents can have catastrophic effects. Not only do companies have to pay fines and damages, but the impacts on the brand's reputation can be long-lasting. That's why Spore.Bio, a Paris-based deeptech startup, is trying to reinvent microbiology testing to avoid the next PR crisis in the food industry. After raising an '8 million pre-seed round ($8.3 million at current exchange rates) a little bit more than a year ago, the company just secured a $23 million Series A round. Singular is leading the round. Point 72 Ventures, 1st Kind Ventures (the family office of the Peugeot family), Station F and Lord David Prior are also participating. Existing investors LocalGlobe, No Label Ventures and Famille C are putting more money in the company as well. The reason why Spore.Bio managed to raise so quickly after its pre-seed round is that there's real customer interest. The startup has already signed a few commercial contracts that...
learn more
